Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS
· Delayed Price · Currency is USD
0.0865
+0.0014 (1.67%)
Aug 15, 2025, 3:53 PM EDT
PVCT Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 0.46 | 0.62 | 0.56 | 0.99 | - | - | Upgrade
|
| Revenue Growth (YoY) | -32.71% | 10.66% | -43.61% | - | - | - | Upgrade
|
| Cost of Revenue | 2.19 | 1.96 | 1.7 | 2.31 | 2.52 | - | Upgrade
|
| Gross Profit | -1.73 | -1.34 | -1.14 | -1.32 | -2.52 | - | Upgrade
|
| Selling, General & Admin | 3.95 | 2.61 | 1.36 | 1.55 | 2.12 | 2.21 | Upgrade
|
| Research & Development | - | - | - | - | - | 2.72 | Upgrade
|
| Operating Expenses | 3.95 | 2.61 | 1.36 | 1.55 | 2.12 | 4.94 | Upgrade
|
| Operating Income | -5.68 | -3.95 | -2.5 | -2.87 | -4.64 | -4.94 | Upgrade
|
| Interest Expense | -0.24 | -0.24 | -0.22 | -0.16 | -0.96 | -1.75 | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 0 | Upgrade
|
| EBT Excluding Unusual Items | -5.92 | -4.19 | -2.71 | -3.03 | -5.6 | -6.68 | Upgrade
|
| Legal Settlements | -0.51 | -0.58 | -0.39 | -0.52 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.06 | 0 | Upgrade
|
| Pretax Income | -6.42 | -4.76 | -3.1 | -3.55 | -5.54 | -6.68 | Upgrade
|
| Net Income | -6.37 | -4.76 | -3.1 | -3.55 | -5.54 | -6.68 | Upgrade
|
| Net Income to Common | -6.37 | -4.76 | -3.1 | -3.55 | -5.54 | -6.68 | Upgrade
|
| Shares Outstanding (Basic) | 420 | 420 | 420 | 419 | 408 | 393 | Upgrade
|
| Shares Outstanding (Diluted) | 420 | 420 | 420 | 419 | 408 | 393 | Upgrade
|
| Shares Change (YoY) | 0.16% | 0.07% | 0.01% | 2.76% | 3.81% | 1.72% | Upgrade
|
| EPS (Basic) | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | Upgrade
|
| Free Cash Flow | -3.09 | -3.28 | -2.57 | -3.04 | -1.01 | -4.09 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 | -0.01 | Upgrade
|
| Gross Margin | - | -216.87% | -204.69% | -133.60% | - | - | Upgrade
|
| Operating Margin | -1234.14% | -639.43% | -447.97% | -290.12% | - | - | Upgrade
|
| Profit Margin | -1383.31% | -771.65% | -556.16% | -359.41% | - | - | Upgrade
|
| Free Cash Flow Margin | -672.25% | -532.15% | -461.17% | -307.52% | - | - | Upgrade
|
| EBITDA | -5.68 | -3.94 | -2.49 | -2.86 | -4.63 | -4.69 | Upgrade
|
| EBITDA Margin | - | - | - | -289.01% | - | - | Upgrade
|
| D&A For EBITDA | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0.24 | Upgrade
|
| EBIT | -5.68 | -3.95 | -2.5 | -2.87 | -4.64 | -4.94 | Upgrade
|
| EBIT Margin | - | - | - | -290.12% | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.